Teva Pharmaceutical Industries Limited's (TEVA) CEO Kare Schultz on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 07/27/22
Teva Pharmaceutical Soars After Inking More Than $4 Billion In Opioid DealsInvestors Business Daily • 07/27/22
Teva Pharmaceutical Soars On $75 Million Opioid Deal In West VirginiaInvestors Business Daily • 07/27/22
Teva's stock jumps 25% after announcing $4.2 billion deal to resolve opioid lawsuitsMarket Watch • 07/27/22
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Teva Pharmaceutical Industries Limited - TEVANewsfile Corp • 07/11/22
Teva to Host Conference Call to Discuss Second Quarter 2022 Financial Results at 8 a.m. ET on July 27, 2022Business Wire • 06/29/22
Teva Announces Promising Interim Results From Its Study PEARL, About the Impact of AJOVY® (fremanezumab)Business Wire • 06/24/22